Literature DB >> 9151839

Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

J Goudsmit1, A de Ronde, E de Rooij, R de Boer.   

Abstract

Viral populations in a human immunodeficiency virus type 1 (HIV-1)-infected individual behave as a quasispecies with a rated distribution of fitness variants. Fitness distributions in naturally occurring viral populations have been difficult to study due to the lack of markers for individual virus clones and complicating inter- and intrahost factors like the presence of multiple cell types with distinct tropisms, differences in route of transmission, and intervening immunity. Here, we quantitated the relative fitness in vivo of three subpopulations of HIV-1 marked by mutations at codons 41 and 215 of reverse transcriptase (RT) directly related to zidovudine resistance in an untreated individual who was infected by a zidovudine-resistant strain transmitted from a donor on therapy. The transmission event did not have a substantial impact on the distribution of mutants within the dominant virus population replicating to high levels in the recipient. The evolution of the RT gene was monitored for 20 months. All 102 clones obtained from the donor and the recipient at the different time points contained the M41L mutation, which is associated with a fourfold reduction in zidovudine sensitivity. The leucine at position 41 was stable, although it was encoded by TTG and CTG triplets that fluctuated in abundance partially due to founder effects of clones with nonsilent mutations at codon 215. Of the three subpopulations in the patient, distinguished by a tyrosine (TAC), aspartic acid (GAC), or serine (TCC) at the 215 position of RT, the relative fitness of the GAC variant was calculated to be 10 to 25% higher than the initial TAC variant, and the relative fitness of the TCC variant was 1% higher than that of the GAC variant. Similar to other RNA viruses, lentivirus populations like HIV-1 in patients with a high virus load apparently consist of a broader spectrum of fitness variants than the 1 to 2% fitness difference sufficient for significant replicative advantage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151839      PMCID: PMC191667     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.

Authors:  G Angarano; L Monno; A Appice; A Giannelli; C Romanelli; C Fico; G Pastore
Journal:  AIDS       Date:  1994-07       Impact factor: 4.177

3.  Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.

Authors:  A Erice; D L Mayers; D G Strike; K J Sannerud; F E McCutchan; K Henry; H H Balfour
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

4.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

5.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Subclonal components of consensus fitness in an RNA virus clone.

Authors:  E A Duarte; I S Novella; S Ledesma; D K Clarke; A Moya; S F Elena; E Domingo; J J Holland
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection.

Authors:  B van Gemen; T Kievits; R Schukkink; D van Strijp; L T Malek; R Sooknanan; H G Huisman; P Lens
Journal:  J Virol Methods       Date:  1993-07       Impact factor: 2.014

8.  Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants.

Authors:  J Wahlberg; J Fiore; G Angarano; M Uhlén; J Albert
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

9.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Authors:  P Kellam; C A Boucher; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  42 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Estimating relative fitness in viral competition experiments.

Authors:  A F Marée; W Keulen; C A Boucher; R J De Boer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Procedures for reliable estimation of viral fitness from time-series data.

Authors:  Sebastian Bonhoeffer; Andrew D Barbour; Rob J De Boer
Journal:  Proc Biol Sci       Date:  2002-09-22       Impact factor: 5.349

4.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect.

Authors:  Hendrik Huthoff; Atze T Das; Monique Vink; Bep Klaver; Fokla Zorgdrager; Marion Cornelissen; Ben Berkhout
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

7.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Authors:  Dongning Wang; Charles B Hicks; Neela D Goswami; Emi Tafoya; Ruy M Ribeiro; Fangping Cai; Alan S Perelson; Feng Gao
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

9.  Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference.

Authors:  Hongyu Miao; Carrie Dykes; Lisa M Demeter; Hulin Wu
Journal:  Biometrics       Date:  2008-05-28       Impact factor: 2.571

10.  Population dynamics of HIV-1 inferred from gene sequences.

Authors:  N C Grassly; P H Harvey; E C Holmes
Journal:  Genetics       Date:  1999-02       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.